Table Info

Table 1.

The top 40 studies in a network analysis of searches for endometriosis and IL-6 as well as endometriosis and IL-6 trans

Endometriosis IL-6-trans			Endometriosis IL-6
Citations	Refs	Similarity	Citations	Refs	Similarity
7	0	100	42	31	100
4	0	10.9	138	51	20.9
16	57	9.4	52	25	20.7
6	27	9.1	43	81	20.4
15	73	7.7	131	64	19.4
3	74	7.3	127	54	18.1
11	61	6.8	85	49	18.1
7	40	6.2	145	36	16.3
13	37	6.2	49	54	16.2
50	54	6	34	43	15.8
16	45	6	38	38	14.7
13	42	5.8	27	36	14.5
7	54	5.6	60	24	14
14	49	5.5	68	41	13.5
13	148	5.5	177	66	13.4
13	28	5.5	75	29	13.2
8	69	5.4	37	67	12.8
0	109	5.4	33	76	12.8
43	162	5.3	134	70	12.6
59	68	5.3	111	49	12.6
15	48	5.2	32	89	12.4
108	37	5.2	230	65	12.4
9	43	5.2	41	28	12.2
73	36	5.1	90	173	12.1
52	44	5.1	228	24	11.9
25	57	5.1	141	63	11.8
27	128	5	137	57	11.8
18	135	5	41	49	11.6
239	125	5	47	49	11.6
38	190	5	35	43	11.4
50	46	4.9	53	54	11.3
9	37	4.9	20	23	11
6	46	4.9	282	271	11
1	0	4.8	22	65	11
1	45	4.8	63	28	11
1	0	4.8	152	150	11
1	87	4.8	57	21	10.9
1	54	4.8	95	60	10.9
13	227	4.8	64	114	10.8
1	46	4.7	35	79	10.6
1	21	4.7	81	160	10.6
1,007	-	228.7	3,552	-	539.3

Multiple search terms were used to identify synonyms and largest returns were utilized. Relative similarities were color coded from strong to weak on a respective blue-red spectrum. Bold numbers at the bottom indicate total sums of the fields above. -: blank cell

Declarations

Acknowledgments

During the preparation of this work, the author used ChatGPT 4 in order to assess readability and identify typographical errors. After using this tool/service, the author reviewed and edited the content as needed and take full responsibility for the content of the publication. The author also thanks to Pubmed and Connected Papers.

Author contributions

RDC: Conceptualization, Analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing—original draft, Writing—review & editing. The author read and approved the submitted version.

Conflicts of interest

The author declares that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Uciechowski P, Dempke WCM. Interleukin-6: A Masterplayer in the Cytokine Network. Oncology. 2020;98:131–7. [DOI] [PubMed]

Tanaka T, Narazaki M, Masuda K, Kishimoto T. Regulation of IL-6 in Immunity and Diseases. Adv Exp Med Biol. 2016;941:79–88. [DOI] [PubMed]

Nara H, Watanabe R. Anti-Inflammatory Effect of Muscle-Derived Interleukin-6 and Its Involvement in Lipid Metabolism. Int J Mol Sci. 2021;22:9889. [DOI] [PubMed] [PMC]

Soliman AM, Fuldeore M, Snabes MC. Factors Associated with Time to Endometriosis Diagnosis in the United States. J Womens Health (Larchmt). 2017;26:788–97. [DOI] [PubMed]

Laganà AS, Garzon S, Götte M, Viganò P, Franchi M, Ghezzi F, et al. The Pathogenesis of Endometriosis: Molecular and Cell Biology Insights. Int J Mol Sci. 2019;20:5615. [DOI] [PubMed] [PMC]

Abramiuk M, Grywalska E, Małkowska P, Sierawska O, Hrynkiewicz R, Niedźwiedzka-Rystwej P. The Role of the Immune System in the Development of Endometriosis. Cells. 2022;11:2028. [DOI] [PubMed] [PMC]

Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878–88. [DOI] [PubMed]

Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J. 1994;300:281–90. [DOI] [PubMed] [PMC]

Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8:1237–47. [DOI] [PubMed] [PMC]

10.

Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18:773–89. [DOI] [PubMed]

11.

Rose-John S, Jenkins BJ, Garbers C, Moll JM, Scheller J. Targeting IL-6 trans-signalling: past, present and future prospects. Nat Rev Immunol. 2023;23:666–81. [DOI] [PubMed] [PMC]

12.

Jones SA, Richards PJ, Scheller J, Rose-John S. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res. 2005;25:241–53. [DOI] [PubMed]

13.

Rose-John S. Therapeutic targeting of IL-6 trans-signaling. Cytokine. 2021;144:155577. [DOI] [PubMed]

14.

Giudice MD, Gangestad SW. Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters. Brain Behav Immun. 2018;70:61–75. [DOI] [PubMed]

15.

Castle RD, Williams MA, Bushell WC, Rindfleisch JA, Peterson CT, Marzolf J, et al. Implications for Systemic Approaches to COVID-19: Effect Sizes of Remdesivir, Tocilizumab, Melatonin, Vitamin D3, and Meditation. J Inflamm Res. 2021;14:4859–76. [DOI] [PubMed] [PMC]

16.

Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010;362:2389–98. [DOI] [PubMed] [PMC]

17.

Bo C, Wang Y. Angiogenesis signaling in endometriosis: Molecules, diagnosis and treatment (Review). Mol Med Rep. 2024;29:43. [DOI] [PubMed] [PMC]

18.

Machado DE, Berardo PT, Palmero CY, Nasciutti LE. Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases. J Exp Clin Cancer Res. 2010;29:4. [DOI] [PubMed] [PMC]

19.

Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2012;122:143–59. [DOI] [PubMed]

20.

Hou W, Jin Y, Kang HS, Kim BS. Interleukin-6 (IL-6) and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell function. J Virol. 2014;88:8479–89. [DOI] [PubMed] [PMC]

21.

Ammendola R, Parisi M, Esposito G, Cattaneo F. Pro-Resolving FPR2 Agonists Regulate NADPH Oxidase-Dependent Phosphorylation of HSP27, OSR1, and MARCKS and Activation of the Respective Upstream Kinases. Antioxidants (Basel). 2021;10:134. [DOI] [PubMed] [PMC]

22.

Cromeens MG, Carey ET, Robinson WR, Knafl K, Thoyre S. Timing, delays and pathways to diagnosis of endometriosis: a scoping review protocol. BMJ Open. 2021;11:e049390. [DOI] [PubMed] [PMC]

23.

Taskin MI, Gungor AC, Adali E, Yay A, Onder GO, Inceboz U. A Humanized Anti-Interleukin 6 Receptor Monoclonal Antibody, Tocilizumab, for the Treatment of Endometriosis in a Rat Model. Reprod Sci. 2016;23:662–9. [DOI] [PubMed]

24.

Taskin MI, Topcu O, Yay A, Erken G, Balcioğlu E, Adali E, et al. Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist. Gynecol Endocrinol. 2015;31:949–54. [DOI] [PubMed]

25.

Ritter A, Kreis N, Louwen F, Yuan J. Obesity and COVID-19: Molecular Mechanisms Linking Both Pandemics. Int J Mol Sci. 2020;21:5793. [DOI] [PubMed] [PMC]

26.

Zhang S, Chen B, Wang B, Chen H, Li Y, Cao Q, et al. Effect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative Colitis: A Randomized Clinical Trial. JAMA. 2023;329:725–34. [DOI] [PubMed] [PMC]

27.

Schreiber S, Aden K, Bernardes JP, Conrad C, Tran F, Höper H, et al. Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease. Gastroenterology. 2021;160:2354–66.e11. [DOI] [PubMed]

28.

McKinnon BD, Bertschi D, Bersinger NA, Mueller MD. Inflammation and nerve fiber interaction in endometriotic pain. Trends Endocrinol Metab. 2015;26:1–10. [DOI] [PubMed]

29.

Matsuzaki S, Pouly JL, Canis M. Persistent activation of signal transducer and activator of transcription 3 via interleukin-6 trans-signaling is involved in fibrosis of endometriosis. Hum Reprod. 2022;37:1489–504. [DOI] [PubMed]

30.

Ahn SH, Monsanto SP, Miller C, Singh SS, Thomas R, Tayade C. Pathophysiology and Immune Dysfunction in Endometriosis. Biomed Res Int. 2015;2015:795976. [DOI] [PubMed] [PMC]

31.

Berg AF, Ettich J, Weitz HT, Krusche M, Floss DM, Scheller J, et al. Exclusive inhibition of IL-6 trans-signaling by soluble gp130FlyRFc. Cytokine X. 2021;3:100058. [DOI] [PubMed] [PMC]

32.

Allocca M, Jovani M, Fiorino G, Schreiber S, Danese S. Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. Curr Drug Targets. 2013;14:1508–21. [DOI] [PubMed]

33.

Colás-Algora N, Muñoz-Pinillos P, Cacho-Navas C, Avendaño-Ortiz J, Rivas Gd, Barroso S, et al. Simultaneous Targeting of IL-1-Signaling and IL-6-Trans-Signaling Preserves Human Pulmonary Endothelial Barrier Function During a Cytokine Storm-Brief Report. Arterioscler Thromb Vasc Biol. 2023;43:2213–22. [DOI] [PubMed]

34.

Ziegler L, Lundström A, Havervall S, Thålin C, Gigante B. IL-6 signalling biomarkers in hospitalised patients with moderate to severe SARS-CoV-2 infection in a single centre study in Sweden. Cytokine. 2022;159:156020. [DOI] [PubMed] [PMC]

35.

Monsour M, Croci DM, Agazzi S, Borlongan CV. Contemplating IL-6, a double-edged sword cytokine: Which side to use for stroke pathology? CNS Neurosci Ther. 2023;29:493–7. [DOI] [PubMed] [PMC]

36.

Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867–72. [DOI] [PubMed]

37.

Scheller J, Garbers C, Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol. 2014;26:2–12. [DOI] [PubMed]